Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.
Revolution Medicines, a US-based cancer treatment developer exploiting research from multiple universities, has filed for a $100m initial public offering on the Nasdaq Global Market.
Terms for the proposed offering have not yet been set.
Founded in 2014, Revolution Medicines is developing small molecule drugs for a range of cancers, with a focus on indications that currently lack a treatment or that where existing therapies are not able to fully inhibit all factors contributing to cancer growth.
…
